Side-by-side comparison of AI visibility scores, market position, and capabilities
Doctronic became the first AI to legally renew prescriptions in the US (190-med formulary, Utah); raised $40M Series B with 300K+ visitors as it expands state by state (March 2026).
Doctronic is a US-based AI telehealth company that has built a regulatory-compliant AI platform for medical consultations and prescription services. The company made history by becoming the first AI to legally renew prescriptions in the United States, initially operating in Utah under a pioneering regulatory framework that allows AI-assisted prescribing for a defined formulary of medications. Doctronic's platform enables patients to consult with an AI for common, well-understood health conditions and receive prescriptions for up to 190 medications without requiring a synchronous visit with a human physician.\n\nDoctronic's platform is designed to navigate the complex intersection of AI capability, medical regulation, and patient safety. Its AI conducts structured medical history intake, symptom assessment, and contraindication screening before generating prescription recommendations that are reviewed within a compliance framework. The platform targets patients seeking convenient, affordable access to prescription renewals and routine care for chronic and common conditions—a massive market given the primary care shortage in the United States. Doctronic operates at the forefront of AI in regulated healthcare, demonstrating that AI can deliver clinically appropriate care within legal guardrails.\n\nDoctronic raised a $40M Series B in 2026 to accelerate geographic expansion and broaden its formulary and condition coverage. With over 300,000 visitors to its platform, Doctronic has demonstrated real consumer demand for AI-mediated healthcare access. The company's Utah-first strategy allowed it to build a compliant, proven model before pursuing expansion to additional states with favorable telehealth regulations. As regulatory frameworks for AI in medicine evolve, Doctronic is positioned as a first-mover with a defensible regulatory and clinical knowledge base.
$500M Series D at $11B valuation (Feb 2026) — largest voice AI funding round ever. $330M ARR; 1M+ developers using the API. Enterprise customers: Deutsche Telekom, Revolut, Meta, Salesforce. Voices in 32 languages; real-time cloning from 1 second of audio.
ElevenLabs was founded in 2022 by Piotr Dabkowski and Mati Staniszewski, two former Google and Palantir engineers who set out to break the language barrier using AI voice technology. The company specializes in AI-powered voice synthesis, cloning, and dubbing, enabling developers and enterprises to generate human-quality speech in over 30 languages. Its core technology combines deep learning models trained on massive speech datasets to produce natural-sounding voices indistinguishable from real humans.\n\nElevenLabs offers a suite of products including its flagship text-to-speech API, voice cloning tools, and an AI dubbing platform that localizes video content while preserving the speaker's original voice. Its products target a broad audience—from indie developers building audio apps to large enterprises deploying voice interfaces at scale. Key differentiators include ultra-low latency streaming synthesis, fine-grained voice customization, and a growing library of pre-built AI voices across accents and styles.\n\nElevenLabs has grown rapidly, surpassing $330M in annualized revenue and serving over 1 million developers. Enterprise clients include Deutsche Telekom, Spotify, and leading media companies. In February 2026, the company closed a $500M Series D at an $11B valuation, cementing its position as the market leader in AI voice. Its APIs power podcasts, audiobooks, video games, and customer service bots worldwide, making ElevenLabs the default infrastructure layer for AI-generated audio.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.